Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
Anemia, complicating the course of chronic kidney disease, is a significant parameter, whether interpreted as subjective impairment or an objective prognostic marker. Renal anemia is predominantly due to relative erythropoietin (EPO) deficiency. EPO inhibits apoptosis of erythrocyte precursors. Stud...
Main Authors: | Patrick Biggar, Gheun-Ho Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Society of Nephrology
2017-09-01
|
Series: | Kidney Research and Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.23876/j.krcp.2017.36.3.209 |
Similar Items
-
Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis
by: Junlan Yang, et al.
Published: (2023-03-01) -
Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitors
by: Akira Takahashi
Published: (2024-02-01) -
Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective
by: Matti Aapro, et al.
Published: (2019-01-01) -
Iron Mining for Erythropoiesis
by: Margherita Correnti, et al.
Published: (2022-05-01) -
Effects of Exogenous Transferrin on the Regulation of Iron Metabolism and Erythropoiesis in Iron Deficiency With or Without Anemia
by: Yihang Li, et al.
Published: (2022-05-01)